Equities research analysts expect Amarin Co. plc (NASDAQ:AMRN) to report sales of $59.10 million for the current quarter, Zacks reports. Three analysts have made estimates for Amarin’s earnings, with estimates ranging from $56.80 million to $63.50 million. Amarin reported sales of $45.24 million during the same quarter last year, which would suggest a positive year over year growth rate of 30.6%. The firm is scheduled to report its next quarterly earnings report on Wednesday, August 1st.
On average, analysts expect that Amarin will report full year sales of $236.67 million for the current fiscal year, with estimates ranging from $231.70 million to $245.80 million. For the next financial year, analysts expect that the business will report sales of $396.60 million per share, with estimates ranging from $283.10 million to $457.50 million. Zacks’ sales averages are an average based on a survey of research analysts that follow Amarin.
Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.08). The business had revenue of $43.80 million for the quarter, compared to analyst estimates of $43.75 million. The company’s revenue for the quarter was up 26.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) EPS.
In other Amarin news, General Counsel Joseph T. Kennedy sold 26,942 shares of the firm’s stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $2.90, for a total value of $78,131.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.08% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of AMRN. Paloma Partners Management Co bought a new position in Amarin in the fourth quarter valued at approximately $141,000. Hoylecohen LLC bought a new position in shares of Amarin during the 4th quarter worth approximately $142,000. Private Advisor Group LLC boosted its stake in shares of Amarin by 81.8% during the 1st quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 28,929 shares during the period. DRW Securities LLC boosted its stake in shares of Amarin by 45.1% during the 1st quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 25,000 shares during the period. Finally, Claraphi Advisory Network LLC boosted its stake in shares of Amarin by 637.3% during the 1st quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 73,738 shares during the period. Hedge funds and other institutional investors own 42.51% of the company’s stock.
Amarin traded down $0.01, reaching $3.26, during midday trading on Monday, MarketBeat Ratings reports. The stock had a trading volume of 48,384 shares, compared to its average volume of 2,106,325. Amarin has a 1-year low of $2.66 and a 1-year high of $4.60. The firm has a market cap of $1.02 billion, a PE ratio of -13.16 and a beta of 0.81. The company has a debt-to-equity ratio of -2.30, a quick ratio of 1.45 and a current ratio of 1.74.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.